>

MEETINGS / EVENTS

RSS

May 05 - 07 2014, 12:00 AM - 12:00 AM

2014 ASA Legislative Conference

>

FDA MEDWATCH ALERTS

April 21, 2014

Lidocaine HCI Injection, USP, by Hospira: Recall - Visible Particulates

Summary:

Lidocaine HCI Injection USP by Hospira Recall Visible Particulates

April 18, 2014

Propofol Injectable Emulsion, USP by Hospira: Recall - Visible Particulates

Summary:

Propofol Injectable Emulsion USP by Hospira Recall Visible Particulates

April 18, 2014

FDA MedWatch - ARKON Anesthesia Delivery System with Version 2.0 Software by Spacelabs Healthcare: Class I Recall

Summary:

FDA MedWatch Class I Recall 4 18 14

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Anesthesiology Continuing Education (ACE) Program

SKU: 30702-14CE

... Read more »

Single Copies, Member Price: $360

ASA Submits Letter to DEA Supporting the Scheduling of Propofol

Thursday, December 23, 2010

In a letter sent to the Drug Enforcement Administration (DEA), ASA expresses its strong support for the DEA’s proposal to place propofol into schedule IV of the Controlled Substances Act and its belief that schedule IV is the proper schedule for the drug. While ASA is extremely supportive of DEA’s proposal, ASA also reminded the Agency that the U.S. health care system and the anesthesia community in particular, are currently recovering from a nationwide shortage of propofol and other related induction agents. Therefore ASA urged the Agency to carefully consider the impact scheduling will have on the supply and distribution of propofol in the near-term in order to avoid unnecessary shortages that could hamper anesthesiologists ability to provide safe patient care. 

Click here to read the full letter.

« Back to Washington Alerts